EarningsQ3 2026 Earnings Report
MX:OMCL Q3 2026 EPS Results
Actual EPS$10.90
Consensus EPS$7.85
Beat/MissBeat by +$3.04
One Year Ago EPS$9.58
MX:OMCL Q3 2026 Revenue Results
Actual Revenue$5.78B
Expected Revenue$5.72B
Beat/MissBeat by +$64.10M
YoY Revenue Growth-0.89%
Earnings Announcement Details
QuarterQ3 2026
Date10/29/2026
TimeBefore Open
Conference CallThursday, October 29, 2026
MX:OMCL Upcoming Earnings
Omnicell's next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:OMCL Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was broadly positive. The company exceeded third-quarter revenue and EBITDA guidance, raised full-year EBITDA and EPS guidance, reported growing and increasingly mature pipeline activity, and highlighted customer validation for Titan XT and OmniSphere. The main challenges were timing variability in back-end-weighted bookings, modest near-term top-line growth, lower fourth-quarter revenue guidance, memory-cost pressure, a modest 340B-related ARR impact, and the multi-year timeline for OmniSphere monetization. The positive operating results, strategic progress, and pipeline commentary significantly outweighed the stated challenges.Company Guidance
Third-Quarter Revenue and EBITDA Beat Guidance
Third-quarter total revenue was $308 million, above the high end of the previously provided $301 million to $307 million guidance range. Non-GAAP EBITDA was $45 million, above the high end of the $32 million to $37 million guidance range.
Strong Profitability and Cash Generation
Non-GAAP earnings per share was $0.58. The company ended the quarter with $315 million in cash and cash equivalents and generated $20 million of free cash flow.
Cost Efficiency and Favorable Mix Supported EBITDA
Third-quarter EBITDA outperformance reflected cost efficiency, favorable customer mix on the product side, favorable gross margins across product and service lines, disciplined spending, expense timing that shifted into the fourth quarter, and efficiencies in G&A and other business-supporting departments.
Full-Year EBITDA and EPS Guidance Raised
The company raised full-year 2026 non-GAAP EBITDA guidance to $187 million-$193 million and non-GAAP EPS guidance to $2.48-$2.56. Management said the EBITDA increase reflected third-quarter cost efficiency and favorable customer mix expected to continue into the fourth quarter.
Full-Year Revenue and ARR Outlook Narrowed
Full-year 2026 guidance was narrowed to total revenue of $1.225 billion-$1.231 billion, product revenue of $684 million-$687 million, service revenue of $541 million-$544 million, and year-end ARR of $660 million-$670 million. Management said the narrower ranges reflected increased visibility with one quarter remaining, rather than a change in the underlying demand picture.
Pipeline Continued to Grow and Mature
The pipeline grew since the prior call, increased modestly in size exiting the third quarter, and improved in maturity in line with expectations relative to the end of the second quarter. Management said the pipeline is meaningfully larger than in recent years and includes large, medium, and small opportunities.
Large Replacement-Cycle Opportunity
Management continues to estimate the total replacement-cycle opportunity at in excess of $2.5 billion for the XT installed base hardware opportunity, excluding market-share gains and incremental OmniSphere monetization.
Titan XT Launch and OmniSphere Progress
The company was days away from its first Titan XT hardware shipment, consistent with the second-half 2026 timing previously outlined, and continues to target the first half of 2027 for OmniSphere general availability. Management said Titan XT and OmniSphere are moving in the right direction.
Growing Customer Interest in the Integrated Platform
Customers are increasingly evaluating Titan XT hardware and OmniSphere as a combined enterprise solution. OmniSphere's enterprise visibility and workforce-efficiency capabilities are gaining traction in the sales cycle, while customer demonstrations and reference customers live on the cloud solution have made competitive conversations more productive.
Customer-Reported Efficiency and Clinical Outcomes
One rural, multi-state community health system realized roughly 70% time savings in its cabinet restock workflow. One large, multi-state regional health system reported a 41% increase in pharmacist-led clinical interventions.
Specialty Pharmacy and Government-Channel Wins
The specialty pharmacy services business contracted with a notable federally qualified health center, which has already generated a referenceable referral. The company also reported continued momentum in its government channel, including additional wins within the Veterans Affairs system.
Install-Base Expansion Wins
The company reported continued third-quarter movement in its install base, including XT expansion wins from an academic medical center in the Northeast and several multi-state health systems.
Leasing Expanded Competitive Flexibility
Leasing has become a meaningful part of the go-to-market approach and is helping move competitive discussions toward clinical capabilities and workforce efficiencies. Management estimated that roughly 30-ish percent of the marketplace is currently involved in leasing transactions, with most of those transactions involving customers of the primary competitor.
Positive Reception to OmniSphere Subscription Pricing
Customers are viewing OmniSphere's subscription-based pricing model favorably because of the predictability and total-cost-of-ownership visibility it offers. The model also gives health systems flexibility to adjust connected assets as their portfolios and footprints change.
Operating Leverage Building
Management said EBITDA is growing meaningfully faster than revenue in 2026, even while top-line growth remains modest, and described this as evidence that operating leverage is building. The company expects leverage to become more visible as the refresh cycle matures over the next few years.
Constructive Customer Investment Environment
Management said medication management remains a priority investment across its customer base, with customers focused on operational efficiency, reliability, and staffing pressures. The capital purchasing environment for these strategic investments was described as constructive, and an increasing number of health systems are planning paths toward cloud deployment.
MX:OMCL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed